1. Li Auto (02015.HK) is reportedly developing its own cloud inference chip.
2. Nanhua Futures (02691.HK): Net profit attributable to shareholders of the parent company was RMB 388 million in the first half of the year, a year-on-year increase of 67.91%.
3. Haixi New Drug (02637.HK): HX9428 received Fast Track designation from the US FDA for the treatment of nAMD.
4. Kelun Biotech (06990.HK): Net profit of RMB 388 million in the first half of 2026, turning a loss into a profit year-on-year.
5. Guoquan (02517.HK): Revenue of RMB 3.947 billion in the first half of 2026, a year-on-year increase of 21.8%; core operating profit of RMB 225 million, a year-on-year increase of 18.3%.
6. Meet Noodles (02408.HK): Revenue of RMB 939 million in the first half of 2026, a year-on-year increase of 33.6%; profit of RMB 63.26 million, a year-on-year increase of 51.2%. 7. Chow Sang Sang (00116.HK): The company expects to record a profit attributable to owners of the company of between HK$2.1 billion and HK$2.2 billion for the first half of 2026, compared to HK$910 million in the same period of 2025.
8. Guotai Junan International (01788.HK): Revenue for the first half of 2026 was HK$3.871 billion, a year-on-year increase of 37%; profit attributable to ordinary shareholders was HK$675 million, a year-on-year increase of 23%.
9. Baihong Industrial (02299.HK): Revenue for the first half of 2026 was approximately RMB12.712 billion, an increase of 34% compared to the same period last year; profit was RMB985 million, an increase of 161.6% compared to the same period last year.
10. Huazhu Group (01179.HK): Revenue for the first half of 2026 was RMB13.1 billion, an increase of 11% compared to the first half of 2025; net profit attributable to Huazhu Group Limited for the first half of 2026 was RMB2.4 billion.
11. Yida China (03639.HK): For the seven months ended July 31, 2026, the Group’s contracted sales amounted to approximately RMB298 million and the Group’s equity contracted sales amounted to approximately RMB294 million.
